Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|December 2, 2016
- Pharmaceutical Technology-12-02-2016
- Volume 40
- Issue 12
Shrink Banders for Labeling Applications
The R Series Shrink banders from PDC International Corporation perform label and neck banding functions at line speeds of 400 to 1000 cpm.
The R Series Shrink banders from PDC International Corporation perform label and neck banding functions at line speeds of 400 to 1000 cpm. The machine can be used to label pharmaceutical vials and ampules. The banders apply 1-3.75-in. diameter bands at heights up to 2.375 in. The machines are engineered to run continuously, with a continuous material web that does not pause for cutting. The banders include ink-jet and thermal-transfer coding, 2D and bar-code scanning, and vision system inspection. Installation qualification and operational qualification documents can also be generated for regulatory compliance. PDC R-Series Shrink banders have the capability to apply thin gauge (1 to 1.5 mils, 25 to 40 micron) banding materials, and are compatible with all shrink sleeve films made from a variety of polymer types.
Articles in this issue
almost 10 years ago
Options in Employee Trainingalmost 10 years ago
Biosimilars Supporting Contract Manufacturers’ Growthalmost 10 years ago
Airlocks for cGMP Facilitiesalmost 10 years ago
Evaluating Mixing in a Single-Use Bioprocessing Systemalmost 10 years ago
Chromatograph Enables Fast Recovery of Target Compoundsalmost 10 years ago
Automated Microscope for Multimodal Imagingalmost 10 years ago
From Bitter to Sweet: Developing a User-Friendly Painkilleralmost 10 years ago
Nurturing the Relationship Between Industry and Regulatorsalmost 10 years ago
Getting involved with pharma standardsalmost 10 years ago
Industry’s role in helping to create standardsRelated to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.